share_log
Moomoo 24/7 ·  Mar 18 10:48
ZyVersa Therapeutics Shares Are Trading Higher After the Company Announced IRB Approval of the Phase 2a Clinical Trial Protocol to Evaluate the Efficacy and Safety of Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment